Schematic structure of PG and target sites of different enzymes (pointed by color arrows). The synthetic enzyme (PBP) is highlighted in red while the lytic. e la Rete di Sorveglianza dell’Antibiotico-Resistenza in Toscana (SMART): . penicilline; J01D consumo di altri beta-lattamici; J01F consumo di macrolidi. sorveglianza sulla diffusione dei batteri resistenti agli antibiotici. lattamasi, che riescono a inattivare molti antibiotici beta-lattamici, tra cui i carbapenemi.
|Published (Last):||26 July 2007|
|PDF File Size:||16.37 Mb|
|ePub File Size:||9.7 Mb|
|Price:||Free* [*Free Regsitration Required]|
Pensiamo che vi sia piaciuta questa presentazione. Per scaricarla, consigliatela, per favore ai vostri amici su un qualsiasi social network.
Pubblicato Gina Sassi Modificato 4 anni fa. Inactivation of PBP-1a and b achieves rapid bactericidal action without the prior filamentation that occurs with agents such as third-generation cephalosporins, which binds primarily to PBP-3 It is susceptible to hydrolysis by DHP- I and thus requires the lattamuci of an inhibitor lattmici this enzyme, betamipron.
This drug, is approved in Japan, China and South Korea. Broad spectrum of activity similar to imipenem but poor activity against Bera. Like other carbapenems, biapenem is not affected by the presence of ESBLs but is labile to hydrolysis by both serine and metallo- carbapenemases. Tomopenem is more stable to hydrolysis by human renal dehydropepti-dase-I than meropenem or imipenem and is bactericidal against P. CS is more stable to hydrolysis by human renal dehydropepti-dase-I than meropenem or imipenem and is bactericidal against P.
The broad spectrum suggest the use for a wide range of infections.
Tomopenem is distributed to the extracellular fluid where many infecting microorganisms reside. The broad spectrum of in vitro activity of tomopenem suggest potential for therapy of a wide range of infections. Lattaamici, further studies are warranted to determine its detailed clinical efficacy. Tomopenme is predominantly distributed to the extracellular fluid in body after intravenous administration. This limited distribution would be favorable property of an antimicrobial agent, since most infecting microorganisms resides in extra cellular space.
A low protein binding ratio would also be favorable property for tomopenem, since the protein unbound, free form of CS in plasma is a pharmacologically active fraction, which achieve rapid equilibrium with drug in extracellular fluid. High affinity for PBPs enhances its activity against multidrug-resistant Gram-positive organisms including MRSA, antkbiotici it retained the typical carbapenem-like spectrum against Gram-negative bacteria including Pseudomonas spp.
ME is active against isolates of many species, including extended spectrum b-lactamase ESBL -producing Enterobacteriaceae, b-lactamase-producing H. Faropenem medoxil formerly faropenem daloxate is an oral prodrug that is rapidly cleaved, releasing the microbiologically active faropenem following absorption in plasma. Faropenem is active against the lwttamici respiratory pathogens, including non—penicillin susceptible S.
Although faropenem exhib- ited higher MIC against penicillin resistant S. Sanfetrinem GVwhich is a trinem b-lactam, can be administered orally as a hexatil ester. Like imipenem, sanfetrinem was found to be stable to TEM-1 and TEM enzyme, and like imipenem and cefixime but unlike cefpodoxime also retained activity against P.
Faropenem is active against the major respiratory pathogens, including penicillin-resistent S. Faropenem is four fold more active than amoxicillin clavulanate eight-fold more active than cefdinir and cefuroxime.
Against penicillin resistant S.
Meropenem – Wikipedia
Ithasexcellentactivityagainstmultidrug-resistant MDR strains of P. Itisknownthatbacteria require ironforgrowthand,underiron- limitedconditions suchas infections inmammalsduringwhichironisboundbyacute-phase reactants suchasferritin,transferrinandotheriron-bindingpro- teinsbacteriausesiderophorestoscavengeforiron. Amongstthe siderophores utilisedbyGram- negativebacteriaarecarbamates and catechols.
Inthes,Glaxoproducedanumberofcatechol- cephalosporins inwhichthecatecholmoietywasattachedtothe 3-position ofthemolecule . Thesecatechol-cephalosporins had outstandingactivityagainstresistantGram- negativebacte- ria, including P.
Since thereleasedcatecholshadpotentialpressoreffects,thedrugs could notbedevelopedforclinicaluse,althoughGlaxodidsyn- thesise compoundsinwhichthecatecholswereattachedtothe side chainatthe7- position whichwasnotaleavinggroup before abandoning theproject . BALutilisesadihydropyridone iron-chelating groupattachedtothe3- positionofamonobactam.
As noted,thisgivesitenhancedactivityagainstmultiresistantnon- fermenters including Acinetobacter, Burkholderia, P. Cumulative Assessment Group refinement.